cemiplimab,fianlimab
sanofi,regeneron
['fianlimab', 'melanoma', 'cemiplimab', 'libtayo', '$regn', 'regeneron']
#regeneron reported #fianlimab (#lag3inhibitor) combined with #libtayo (#cemiplimab) demonstrates greater than 60% response rates in two independent cohorts of patients with advanced #melanoma na ve to #pd1 or #pdl1 #inhibitors #esmo22 $regn 
Follow top-line development in the oncology commercial domain. Gain entry to KOL discussions, including both medical professionals and business leaders.